Literature DB >> 12210381

Patterns of nerve conduction abnormalities in POEMS syndrome.

Jia-Ying Sung1, Satoshi Kuwabara, Kazue Ogawara, Kazuaki Kanai, Takamichi Hattori.   

Abstract

Polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome is a rare cause of demyelinating and axonal neuropathy. POEMS syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP) cause peripheral nerve demyelination, and the electrodiagnostic findings may therefore be similar, but the two disorders are distinct. To elucidate the electrodiagnostic features of POEMS syndrome, we reviewed nerve conduction studies of 8 patients, and compared their results with those in 42 patients with CIDP. The patients with POEMS syndrome showed (1) slowing of nerve conduction that was more predominant in the intermediate than distal nerve segments, (2) rare conduction block (6% of the tested nerves), and (3) more severe attenuation of compound muscle action potentials in the lower than upper limbs. Findings in the CIDP patients were characterized by multifocal conduction slowing that was occasionally dominant distally, frequent conduction block (44% of tested nerves), and less discrepancy between upper and lower limb nerves. The pattern of nerve conduction abnormalities differs between these disorders. Recognition of these typical patterns may be helpful for early diagnosis of POEMS syndrome. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210381     DOI: 10.1002/mus.10182

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

2.  Increases in M-wave latency of biceps brachii after elbow flexor eccentric contractions in women.

Authors:  Karina Kouzaki; Kazunori Nosaka; Eisuke Ochi; Koichi Nakazato
Journal:  Eur J Appl Physiol       Date:  2016-03-19       Impact factor: 3.078

Review 3.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

4.  POEMS syndrome: cryoglobulinemia an unusual association.

Authors:  M Iqbal; S Bilal; M Hennessy
Journal:  Ir J Med Sci       Date:  2010-04-07       Impact factor: 1.568

Review 5.  Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.

Authors:  Satoshi Kuwabara; Angela Dispenzieri; Kimiyoshi Arimura; Sonoko Misawa; Chiaki Nakaseko
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 6.  Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Authors:  Andreas J Steck; Adam Czaplinski; Susanne Renaud
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

7.  Nerve pathologic features differentiate POEMS syndrome from CIDP.

Authors:  Ezequiel A Piccione; Janean Engelstad; Peter J Dyck; Michelle L Mauermann; Angela Dispenzieri; P James B Dyck
Journal:  Acta Neuropathol Commun       Date:  2016-10-31       Impact factor: 7.801

8.  Temporal dispersion in demyelination of POEMS syndrome and Castleman disease.

Authors:  Yue Hui Lau; Hazfadzila Mohd Unit; Lay Peng Lee; Weng Khean Loh; Fu Liong Hiew
Journal:  Clin Neurophysiol Pract       Date:  2020-05-31

Review 9.  An update on the diagnosis and management of the polyneuropathy of POEMS syndrome.

Authors:  Federica Cerri; Yuri Matteo Falzone; Nilo Riva; Angelo Quattrini
Journal:  J Neurol       Date:  2018-09-27       Impact factor: 4.849

10.  Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome.

Authors:  Qin Wang; Peng Liu; Li-Li Ji; Shuai Wu; Guo-Dong Feng; Xin Wang; Ji-Hong Dong
Journal:  Chin Med J (Engl)       Date:  2019-07-20       Impact factor: 2.628

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.